REDHILL B.S.ADR 10/IL-,01 Forum: Community User: MeisterYoda1

RedHill Biopharma (Nasdaq: RDHL) announces receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib and RHB-107 (upamostat) as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus. The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted. · The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted · Enrollment in opaganib’s global Phase 2/3 study in hospitalized patients with severe COVID-19 is almost 100% complete · RHB-107’s ongoing Phase 2/3 study is enrolling U.S. non-hospitalized patients with symptomatic COVID-19 that do not require supplemental oxygen · Opaganib and RHB-107 are novel, oral, host-targeted drug candidates expected to be effective against emerging viral variants · Opaganib and RHB-107 potentially cover the vast majority of affected COVID-19 patients “There is an urgent need for oral COVID-19 treatments for patients inside and outside of the hospital setting,” said Danielle T. Abramson, Ph.D., VP, Intellectual Property & Research at RedHill. “With two novel oral COVID-19 therapeutics in late clinical-stage development, RedHill stands at the forefront of research for COVID-19 treatments. We are very pleased with the new intellectual property protection which extends until at least 2041. The Company has also filed for protection under the Patent Cooperation Treaty (PCT) and has the option of applying in the member countries thereof.”

RedHill Biopharma (Nasdaq: RDHL) announces presentation of new analyses of Aemcolo® (rifamycin) and Movantik® (naloxegol) data at Digestive Disease Week (DDW) 2021. The Company presented three posters: Aemcolo poster (poster number: Fr244): Development of a New Travelers’ Diarrhea (TD) Clinical Severity Classification and its Utility in Confirming Rifamycin SV Efficacy “Antibiotics are the mainstay of treating bacterial TD; due to growing resistance, they should be reserved for use in more severe cases of the disease,” said Professor Herbert L. DuPont, Director of the Center for Infectious Diseases, University of Texas Houston School of Public Health. “In order to help direct treatment to the most appropriate patients, we developed a new severity classification tool able to support accurate prognosis of disease course and resolution, based on extensive patient data from two Phase 3 trials in Travelers’ Diarrhea, providing significant potential clinical utility. We then used the new classifications to assess the efficacy of rifamycin, reconfirming highly statistically significant efficacy across both newly reclassified moderate and severe patient groups.” Movantik posters: Poster 1 (Poster Number: Sa059): Naloxegol Achieved Rapid and Sustained Improvement of Opioid-Induced Constipation (OIC) Symptoms: A Pooled Analysis of Two Global Randomized Placebo-Controlled Trials Poster 2 (Poster Number: Sa058): Rapid Onset of Time to First Spontaneous Bowel Movement (SBM) and Predictable Efficacy of Naloxegol: Pooled Analysis of Two Global Randomized Controlled Trials “These two new analyses demonstrate rapid and sustained efficacy of naloxegol for a broad range of bothersome OIC symptoms, positively impacting patient care. Given the challenge of OIC symptoms, early symptom relief is an important therapeutic consideration” said Prof. William D. Chey, Director of the GI Physiology Laboratory at the University of Michigan, and former Co-Editor-in-Chief of the American Journal of Gastroenterology.

Immerhin nähern wir uns allmählich der 6€ 😁

Bin wieder bei meinem EK 🎉🍻👍🤪

Studiencompletion wurde von Juni auf Juli verschoben. https://clinicaltrials.gov/ct2/history/NCT04467840?A=43&B=44&C=Side-by-Side#StudyPageTop Trotzdem: Durchhalten, es wird sich lohnen :-)

RedHill Biopharma (NASDAQ: RDHL) will report its first quarter 2021 financial results and operational highlights on Thursday, May 27, 2021. The Company will host a webcast on Thursday, May 27, 2021 at 8:30 a.m. EDT, during which it will present key highlights for the first quarter 2021. The webcast and slides will be broadcasted live on the Company's website: http://ir.redhillbio.com/events and available for replay following the call for 30 days. To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call: United States: +1-877-870-9135; International: +1-646-741-3167 and Israel: +972-3-530-8845; the access code for the call is: 8506238.

Leider haben wir den laufenden Abwärtstrend noch nicht gebrochen. Hoffen wir auf morgen.

Das hoffen wir❗

Die drücken den Kurs bewusst. Da wollen noch einige günstig hinein. Bestimmt wird es irgendwann richtig zünden.

Und wieder nach unten😭😬

HC Wainwright & Co. Initiates Coverage On Redhill Biopharma with Buy Rating, Announces Price Target of $23 https://www.benzinga.com/news/21/05/21170674/hc-wainwright-co-initiates-coverage-on-redhill-biopharma-with-buy-rating-announces-price-target-of-2 Zwei weitere orale Wirkstoffe werden von RedHill Biopharma entwickelt - einer für schwere Covid-19-Infektionen bei Krankenhauspatienten und der andere für Patienten zu Hause mit leichten Infektionen. Das erste, Opaganib (Yeliva), hat eine globale Phase-2/3-Studie für Krankenhauspatienten durchgeführt. In Phase 2 wurde gezeigt, dass das Medikament bei Patienten, die Sauerstoff benötigen, sicher ist und den Sauerstoffbedarf bis zum Ende des Behandlungszeitraums wirksam verringert. https://www.dailypioneer.com/2021/page1/many-oral-drugs-to-blunt-virus-attack-likely-by-year-end.html

Hört sich gut an!

Stimmt Luigi 11 dollar wäre vorerst🔝🔝

Die Hälfte wäre schon top

Wow. 23 Dollar

Neues Kursziel von 23 Dollar lesen wir doch gerne. ✌🏽